General Diabetes Treatment Recommendations: Type 1 Diabetes
Patients who have type 1 diabetes should start insulin therapy at
the time of diagnosis,
and
insulin therapy will need to be continued for the life of the
patient. Research has shown that as many as 74% of people who have
had type 1 diabetes for five years or longer still secrete tiny
amounts of insulin,
and some patients who have type 1 diabetes secrete an amount of
insulin that is clinically important,
but insulin therapy is still necessary for treatment of type 1
diabetes patients. Injected insulin acts as a replacement for the
insulin the body doesn’t make or can’t use properly. It is
effectively used to treat type 1 or type 2 diabetes. Different types
of insulin are available. Some types act quickly, and these can help
control blood glucose levels at mealtime. Others types act over a
longer period. These types control blood glucose levels throughout
the day and night.
Begin insulin therapy early
74% of people who have had type 1 diabetes
for
5+ years still produce insulin
But supplementing this production is still
necessary |
|
Patients who have type 1 diabetes must use insulin and for patients
who have type 2 diabetes, initiation of pharmacologic therapy with
an oral hypoglycemic at the time of diagnosis is usually
recommended. Type 2 diabetes is managed not only by medications, but
through lifestyle changes, like weight loss, exercise, and possibly
smoking cessation. These interventions can help with glycemic
control and they have value for diabetic patients aside from their
role in glycemic control. However, for the reasons listed below,
glycemic control in type 2 diabetes may require the use of
medications (sometimes multiple medications), and many patients who
have type 2 diabetes will progress to type 1 diabetes and eventually
need insulin.
Pancreatic beta-cell dysfunction is often significantly decreased by
the time of diagnosis.
Remission of type 2 diabetes requires long-term changes in lifestyle
like a significant level of weight loss but this is complicated by
the fact that many people, whether or not they have diabetes, are
unable to lose weight and/or adhere to an exercise program or stop
smoking.
The
natural history of type 2 diabetes involves progressive beta cell
dysfunction and increased insulin resistance over time, which may be
slowed by the combination of medication and lifestyle improvements.
Early pharmacologic treatment that is started before HbA1c becomes
significantly elevated can improve long-term glycemic control and
decrease the risk of long-term complications.
Insulin and Insulin Therapy Goals and Methods
Glycemic control is the goal of treatment for diabetes, but not all
patients can reach the standard hemoglobin A1c (also called A1c)
range-and a lower or higher A1c may be considered acceptable,
depending on the patient’s age, co-morbidities, the duration of
their disease, and other factors.
The
insulin therapy that is currently recommended is often called
intensive insulin therapy, and it is intended to mimic as closely as
possible the normal physiological profile of insulin secretion and
release. This approach has been shown to produce better glycemic
control and to significantly reduce the risk of developing diabetic
nephropathy, neuropathy, and retinopathy and the cardiovascular
complications of diabetes.
The basic goals/objectives and methods of intensive insulin therapy
are:
A
primary goal of therapy is to achieve an A1c of <7%.
New
insulin users need to figure just how much insulin they need to
affect the desired changes to their blood glucose levels, so many
healthcare providers will recommend a pre-meal blood glucose level
of 90-130 mg/dL and a post-meal blood glucose of <180 mg/dL to
minimize the risk of hypoglycemia.
To
achieve these goals, a patient with diabetes may be advised to
administer a twice a day injection of an intermediate- or
long-acting insulin to provide a basal level of insulin or an
infusion pump delivering a continuous basal level of rapid-acting
insulin. Prandial insulin before each meal may include a
rapid-acting or short-acting insulin. And, insulin analogues is now
commonly used and is replacing the use of human insulin in the
United States.
Goals of intensive insulin therapy:
Hemoglobin A1c (or “A1c”) of <7%
Pre-prandial glucose level of 90-130 mg/dL
Post-prandial glucose level of 70-180 mg/dL
Methods:
Twice daily injection of an intermediate-
or long-acting insulin, or an insulin pump delivering
continuous insulin
Rapid-acting or short-acting prandial
insulin before each meal
The use of insulin analogues is recommended
|